What Is the CBD Dosing Required for Effective Pain Relief ? Damian McNamara, CME, Laurie Barclay, MD Posted: 12/14/2018 Clinical Context The effects of cannabis in humans include euphoria, increased sensitivity to external experience, relaxation, and potential for addiction. Cannabidiol is a compound in the cannabis plant that lacks euphoric and addictive qualities and that may be useful to treat conditions including chronic pain, nausea, epilepsy, psychosis, and anxiety. The optimal therapeutic dose of CBD has not yet been determined, and it has been used in a wide dose range from 2.85 to 50 mg/kg/day. The therapeutic effects of CBD appear to emanate from its interaction [...]
Lire la suiteInteractions du CBD avec des médicaments sous ordonnance Source : blog-cannabis.com, repris sur Principesactifs.org, 2019 Le CBD est considéré comme bénin, mais il existe beaucoup d’interactions médicamenteuses à éviter avec les médicaments sous ordonnance… "Le CBD fait fureur, ce cannabinoïde non toxique a une tonne d’avantages médicaux. Les gens de tous âges utilisent le CBD pour traiter des problèmes médicaux graves comme l’épilepsie, la maladie de Parkinson, ainsi que des problèmes de santé mentale comme l’anxiété, la dépression et la toxicomanie. Mais il est important d’apprendre comment il peut interagir avec d’autres médicaments sous ordonnance." https://www.principesactifs.org/interactions-du-cdb-avec-des-medicaments-sous-ordonnance/
Lire la suiteCannabidiol (CBD) : analyse de situation Frank ZOBEL, Luca NOTARI, Eva SCHNEIDER, Ocyna RUDMANN Addiction Suisse, Lausanne, janvier 2019 Rapport de recherche N° 97 https://www.addictionsuisse.ch/fileadmin/user_upload/DocUpload/Rapport-CBD-final.pdf Table des matières Liste des tableaux Liste des graphiques 1 Introduction 2 Méthode 3 Brève analyse de la littérature sur les effets du Cannabidiol (CBD) 3.1 Méthode 3.2 Usages du CBD et effets 3.3 Pourquoi prendre du CBD? Amélioration de la qualité de vie/réduction de certains symptômes dans le domaine somatique Amélioration de la qualité de vie/réduction de certains symptômes dans le domaine psychique Traitement/prévention de maladies chroniques et neurodégénératives, renforcement du système immunitaire . Traitement de troubles neurologiques diagnostiqués . Autres 3.4 Que sait-on de ces effets à ce jour? 3.5 Le CBD peut-il [...]
Lire la suiteIs cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms ? José Alexandre S. CRIPPA,· Jaime E. C. HALLAK, · Antônio W. ZUARDI · Francisco S. GUIMARAES, · Vitor TUMAS, · Rafael G. dos SANTOS European Archives of Psychiatry and Clinical Neuroscience, 2019, 269(1) DOI : 10.1007/s00406-019-00982-6 © Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract Parkinson’s disease (PD) is a chronic neurodegenerative disorder characterized by motor symptoms such as bradykinesia, rest tremor, postural disturbances, and rigidity. PD is also characterized by non-motor symptoms such as sleep disturbances, cognitive deficits, and psychiatric disorders such as psychosis, depression, and anxiety. The pharmacological treatment for these symptoms is [...]
Lire la suiteAn Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies Kerstin IFFLAND, Franjo GROTENHERMEN Cannabis and Cannabinoid Research, 2017, 2, (1), 139–154. DOI: 10.1089/can.2016.0034 https://www.liebertpub.com/doi/10.1089/can.2016.0034?utm_source=sfmc&utm_medium=email&utm_campaign=CAN%20OA%20Feb%201%202019&d=2/1/2019&mcid=1909944349 Abstract Introduction: This literature survey aims to extend the comprehensive survey performed by Bergamaschi et al. in 2011 on cannabidiol (CBD) safety and side effects. Apart from updating the literature, this article focuses on clinical studies and CBD potential interactions with other drugs. Results: In general, the often described favorable safety profile of CBD in humans was confirmed and extended by the reviewed research. The majority of studies were performed for treatment of epilepsy [...]
Lire la suiteAntidépresseur-like effect induced by Cannabidiol is dependent on brain serotonin levels. A.J. Sales, C. C. Crestani, F. S. Guimaraes, S. R.L. Joca, Progress in Neuropsychopharmacology & Biological Psychiatry, 2018 Aug 30; 86: 255-261. Doi: 10.1016/j.pnpbp.2018.06.002 https://www.ncbi.nlm.nih.gov/pubmed/29885468 PMID : 29885468 Abstract Cannabidiol (CBD) is a compound of Cannabis sativa with relevant therapeutic potential in several neuropsychiatric disorders including depression. CBD treatment has shown significant antidepressant-like effects in different rodent preclinical models. However, the mechanisms involved in CBD-induced antidepressant effects are still poorly understood. Therefore, this work aimed at investigating the participation of serotonin (5-HT) and/or noradrenaline (NA) in CBD-induced antidepressant-like effects in [...]
Lire la suiteCannabis and the Anxiety of Fragmentation - A Systems Approach for Finding an Anxiolytic Cannabis Chemotype, B. S. Kamal, F. Kamal, D. E. Lantela, Frontiers in Neuroscience, 2018, 12, article 730. https://doi.org/10.3389/fnins.2018.00730 Abstract : Cannabis sativa is a medicinal herb with a diverse range of chemotypes that can exert both anxiolytic and anxiogenic effects on humans. Medical cannabis patients receiving organically grown cannabis from a single source were surveyed about the effectiveness of cannabis for treating anxiety. Patients rated cannabis as highly effective overall for treating anxiety with an average score of 8.03 on a Likert scale of 0 to 10 (0 = not effective, [...]
Lire la suite